卖什么
Kernal is creating mRNA 2.0 therapies that work in specific cells
商业模式拆解
买家：谁掌握预算？
Pharma and biotech partners who co-develop and license mRNA therapeutics; Kernal seeks tailored partnerships with companies sharing its vision.
触发点：什么让他们现在购买？
Ex vivo cell therapies are slow to manufacture, costly and limited to specialized centers; in vivo programming aims to remove these barriers.
工作流：什么输入变成什么输出？
Deliver an mRNA sequence in targeted lipid nanoparticles to specific tissues and cells, with AI-designed sequences ensuring selective translation only in target cells, to program in vivo CAR-T cells for cancer and autoimmune disease.
经济账：省了什么，怎么收费？
Therapeutics developer: value from pipeline assets and partnerships; funded in part by an ARPA-H award of up to $48 million for lower-cost in vivo CAR T-cell therapies.
渠道：怎么接触到客户？
Partnership-led: each partnership is tailored to the partner's expertise and program needs; contact via hello@kernalbio.com.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2020 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.